Clinical Research Directory

Inclusion Criteria: 1. Adult, male or female patients with non-dystrophic myotonic disorders planned to be started on Namuscla according to the approved SmPC 2. Patients already receiving Namuscla/mexiletine for the treatment of NDM; (for patients on mexiletine other than Namuscla, only those who switch to Namuscla will be enrolled). 3. Patients who understand and are willing to provide informed consent. Exclusion Criteria: 1. Patients who are enrolled or participating in any other clinical trial for an investigational product. - 2. Hypersensitivity to mexiletine, or to any of the excipients of Namuscla, or hypersensitivity to any local anaesthetic 3. Ventricular tachyarrhythmia 4. Atrial tachyarrhythmia, fibrillation or flutter 5. Complete heart block (ie, third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 240 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block), 6. Myocardial infarction (acute or past), or abnormal Q-waves 7. Symptomatic coronary artery disease 8. Heart failure with reduced ejection fraction \<50% 9. Sinus node dysfunction (including sinus rate \< 50 bpm) 10. Patients receiving drugs that can induce torsades de pointes 11. Patients receiving medicinal products with narrow therapeutic index (ie, theophylline, tizanidine, digoxin, lithium, phenytoin or warfarin) 12. Patients who are pregnant or lactating.